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Abstract： 
Trypanosoma musculi, a common blood flagellate found in mice, is similar in 
morphology and life cycle to the rat trypanosome T. lewisi. Both species belong to the 
subgenus Herpetosoma and, as T. lewisi has recently been shown to be a zoonotic 
pathogen, there is concern that T. musculi could also be potentially infective to 
humans. To test this hypothesis, a well-established method, the normal human serum 
(NHS) incubation test, was carried out which distinguishes human and non-human 
infective trypanosomes. We found that T. musculi could grow in 0.31% NHS in vitro, 
and even kept their infectivity to mice after incubation with 10% NHS for 24 hours. In 
in vivo experiments, T. musculi were only slightly affected by NHS injection, 
confirming that it was less sensitive to the NHS than T. b. brucei, but more sensitive 
than T. lewisi. This resistance probably does not rely on a restricted uptake of ApoL-1. 
Due to this partial resistance, we cannot definitively confirm that T. musculi has the 
potential for infection to humans. As resistance is less than that of T. lewisi, our data 
suggest that it is unlikely to be a zoonotic pathogen although we would advise caution 
in the case of immunocompromised people such as AIDS and cancer patients. 
 
1. Introduction 
Trypanosoma lewisi is a rat-specific haemoflagellate that is distributed globally. 
When a number of human infection cases were reported, T. lewisi was suggested as a 
potential human pathogen (Lun, et al., 2009, Truc, et al., 2013). Currently, 
experimental evidence demonstrates that this rat trypanosome was resistant to lysis by 
normal human serum (NHS) and apolipoprotein L-1 (ApoL-1) both in vitro and in 
vivo and was therefore considered an opportunistic zoonotic trypanosome (Lun, et al., 
2015). However, an important question is whether any other animal trypanosomes are 
also human infective. 
The answer is yes, although it is considered to have occurred by accident. For 
instance, Trypanosoma evansi, which is a member of subgenus Trypanozoon 
alongside the two well-known human pathogens T. b. gambiense and T. b. rhodesiense, 
can infect humans possessing both the normal ApoL-1 gene and a mutated version 
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(Vanhollebeke, et al., 2006; Van Vinh Chau, et al., 2016; WHO, 2005). Patients have 
also been found with mixed infections of T. congolense and T. b. brucei (Truc et al., 
1998). However, we were interested whether T. musculi, a mouse trypanosome with 
morphological characteristics similar to those of T. lewisi can naturally infect humans. 
Both T. musculi and T. lewisi belong to the subgenus Herpetosoma and they share 
many biological characteristics. In fact, some human cases infected with 
trypanosomes have only been identified as T. lewisi-like trypanosomes with the 
correct species being unknown (Sarataphan, et al., 2007, Verma, et al., 2011). 
Identification of these trypanosomes were mainly based on morphology and 
molecular diagnostics (Howie, et al., 2006). However, previous studies from our lab 
have shown that it is very difficult to distinguish T. lewisi from T. musculi either by 
morphological characteristics or by 18S DNA barcoding (Hong, et al., 2017). 
Therefore, whether these cases were caused by T. lewisi or T. musculi infection 
remains questionable. To address the question of human infection, the use of the NHS 
trypanolysis assay on T. musculi is the best option. 
In fact, resistance to trypanolysis by NHS has long been considered the 
distinctive feature that can define the human infective trypanosomes from non-human 
infection species. It has been demonstrated that T. b. gambiense and T. b. rhodesiense, 
are naturally resistant to lysis by NHS (Capewell, et al., 2013, De Greef, et al., 1992, 
Laveran and Mensnil, 1912 ). The active component, ApoL-1, can permeabilize the 
lysosomal and mitochondrial membranes of trypanosomes resulting in death for the 
NHS sensitive species (Perez-Morga, et al., 2005, Thomson and Finkelstein, 2015, 
Uzureau, et al., 2013；Vanhamme, et al., 2003, Vanwalleghem, et al., 2015; Xong, et 
al., 1998). In order to determine the potential risk that T. musculi poses for human 
infection, we investigated the effect of NHS and ApoL-1 on this rodent trypanosome.  
 
2. Materials and methods 
2.1. Animals and Trypanosomes 
All mice (Swiss Webster, 20-25 g) and rats (Sprague Dawley, 150-200 g) were 
purchased from the Center of Experimental Animals for the Guangdong province. 
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They were handled strictly according to protocols approved by the Laboratory Animal 
Use and Care Committee of Sun Yat-Sen University under the license for grant 
Number 31672276. The Partinico II strain of T. musculi used in this investigation was 
originally obtained from the London School of Hygiene and Tropical Medicine 
(Krampitz, 1969). It was gifted by Prof. Philippe Vincendeau of Université de 
Bordeaux, France. T. musculi (Partinico II) and T. lewisi (CPO02) were harvested 
from the infected blood of mice and rats respectively by centrifugation. In brief, red 
blood cells were pelleted at 170 g for 10-15 min, the parasite-containing supernatant 
was carefully transferred to a clean tube and spun at 800 g for 5 min. The 
trypanosomes were washed twice with serum-free RPMI-1640. 
2.2. DNA extraction, PCR amplification and sequencing of 18S rDNA 
    DNA samples of trypanosomes were isolated as described previously (Hong et 
al., 2017). Primers (F: 5'-GGATAACAAAGGAGCAGC-3', R: 
5'-GGATAACAAAGGAGCAGC-3') were designed using Primer Premier 5 to 
amplify an 834-bp specific region of the 18S rDNA gene of T. lewisi. PCR was 
carried out in a 25 μl reaction mixture containing 12.5 μl PrimeSTAR Max Premix 
(TAKARA, Japan), 6.25 pmol of each primer, 100 ng template DNA. Amplification 
was performed for 35 cycles (98 oC for 10 s, 55 oC for 15 s, and 72 oC for 10 s). PCR 
products were analyzed by gel electrophoresis using a 1% (w/v) agarose gel for 20 
min at 110 V and sent for sequencing. Sequenced amplicons were aligned with 
reference sequences of T. rangeli (EU867803), T. musculi (AJ223568) and T. lewisi 
(KP098535, GU252209-GU252215, HQ437158, AJ009156, AB242273 and 
KP098536), using MEGA 5.2 software. Haplotype network analyses were performed 
using POPART. 
2.3. Normal human sera and trypanocidal assays 
A pool of freshly collected serum from healthy adult volunteers was prepared 
using standard procedures. The trypanolytic activity of the NHS was confirmed by 
using an in vitro assay with T. b. brucei 427 strain where over 90% were lysed after an 
incubation at 37 oC for 4 h (Lun, et al., 2015). NHS was aliquoted and stored at -80 oC 
before use. 
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In vitro cultured trypanosomes (2×105/ml) were incubated with RPMI-1640 
medium complemented with a serial dilution of NHS (10%, 5%, 2.5%, 1.25%, 0.63%, 
0.31%, and 0%) at 37°C with 5% CO2. The numbers of trypanosomes were counted 
using a haemocytometer by microscopy. 
After being supplemented with 10% NHS or 10% FBS (control) at 37°C for 24 
hours, trypanosomes were then injected into mice intraperitoneally. Parasitemia was 
monitored daily and parasites were found in all mice on the eighth (FBS) and tenth 
(NHS) day post-infection. 
In vivo assays were also carried out. Each mouse was intraperitoneally inoculated 
with 1×105 T. musculi. The parasitemia usually reached 1×106 trypanosomes/ml in 3 
days, and then each mouse was i.p. injected with 0.5 ml fresh NHS. Parasitemia was 
then monitored daily, until sacrificed 30 days later. Each control mouse was treated 
with 0.5 ml FBS instead of NHS. 
2.4. ApoL-1 endocytosis 
Parasites (5×106) were incubated in RPMI-1640 medium supplemented with 5% 
NHS or FBS at 37°C for 1 hour. All trypanosomes were harvested by centrifugation 
and washed twice with PBS and analyzed by SDS-PAGE. After electrophoresis, 
samples were blotted onto PVDF membranes and proteins were detected with an 
ApoL-1 polyclonal antibody (1:1000 dilution, Proteintech, China), HRP-conjugated 
2nd antibody (Proteintech, China) and the reaction was detected using ECL 
(Thermofisher, USA). 
2.5. Statistical analysis 
 Statistical analysis was performed using SPSS statistical software 10.0 (SPSS Inc, 
Chicago). The time of disappearance and relapse of parasitaemia in each group was 
analyzed by one-way-ANOVA, independent sample t test, and paired-sample t test. 
For all analyses, p < 0.05 was considered significant. 
 
3. Results 
Firstly, we aligned the 18S rDNA of T. lewisi and T. musculi with the published 
sequences from human infective T. lewisi-like trypanosomes (Howie, et al., 2006). We 
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amplified the 18S fragment from T. lewisi CPO02, CPO04, CPO06, CPO07, T. 
musculi Partinico II, ATCC 30148, ATCC 30181, and ATCC 30182. Other available 
18S sequences of T. lewisi, T. lewisi-like and T. musculi were downloaded from the 
NCBI, while T. rangeli was used as an outgroup. There are 3 polymorphic sites 
among the T. musculi, T. lewisi and T. lewisi-like trypanosomes (Fig.1A), and these 
represent 4 nodes in a haplotype network (Fig.1B). Interestingly, one T. lewisi 
(WC365 (accession number KP098535)) showed 100% identity to four other T. 
musculi sequences. These findings confirmed the difficulty in distinguishing these two 
parasites from each other using the 18S rDNA sequence. More importantly, the human 
infective T. lewisi-like trypanosomes showed 100% identity to four known T. lewisi 
sequences, but not to the one isolated from rodents in the same house where the 
patient lived. 
Therefore, we consider that T. musculi may share other similar biological 
characteristics with T. lewisi, e.g. the resistance/tolerance to fresh NHS. In this study, 
we tested four available T. musculi strains, Partinico II, ATCC 30148, ATCC 30181 
and ATCC 30182. During a 6-hour incubation in 2.5% NHS, over half (51.1% - 
82.9%) of the trypanosomes (105) were lysed, but 16.2% - 24.1% trypanosomes 
survived even 24 hours after incubation (Table 1 & Fig. S1). Therefore, the resistance 
of T. musculi strains to the lysis by NHS in vitro was considered to be at an 
intermediate level when compared with T. b. brucei and T. lewisi (Table 1). In order to 
further understand the resistance in T. musculi, we performed a detailed comparison 
with T. b. brucei and T. lewisi. As shown in Fig. 1, T. b. brucei was highly sensitive to 
NHS and was lyzed even in 0.31% NHS, while T. lewisi was completely tolerant to 
10% NHS and exhibited continuous growth in 5% NHS. Interestingly, the T. musculi 
(Partinico II strain) was tolerant to 0.63% NHS and continuously grew in 0.31% NHS 
(Fig. 2) further supporting the notion that T. musculi has an intermediate level of 
resistance. 
To test the effect of NHS on infectivity of T. musculi (Partinico II strain) in mice, 
parasites were pre-incubated with both 10% NHS and 10% FBS (control) in vitro for 
24 hours and then inoculated into mice, respectively. Parasitemia in the mice 
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inoculated with NHS-treated T. musculi was observed from day 10 to day 25 after 
inoculation but was delayed by 2-3 days compared with the group of mice inoculated 
with 10% FBS treated T. musculi. Moreover, in comparison with the T. musculi 
treated with FBS, a significantly lower parasitemia was observed in the mice 
inoculated with the T. musculi treated with NHS serum (Fig. 3). An in vivo assay was 
also performed by inoculation of 500 µl NHS into each mouse infected with T. 
musculi (Partinico II strain) when the parasitemia of the infected animal reached 
2×106 trypanosomes/ml. A significantly lower parasitemia was found in the mice 
inoculated with NHS than those inoculated with FBS, while the duration of the 
parasitemia was similar (Fig. 4). These results fall into a similar category which were 
defined as sub-resistance in previous studies on T. brucei (Hawking, 1976). 
Unfortunately, we do not have in vivo NHS resistance data for the three T. musculi 
ATCC strains as they were unable to infect mice. However, our results from the T. 
musculi Partinico II strain suggest that T. musculi has a much lower sensitivity to lysis 
by NHS than T. b. brucei but a higher sensitivity than T. lewisi. 
In order to understand the potential mechanism of resistance of T. musculi to 
NHS, we compared the endocytotic activity of ApoL-1 in these trypanosomes. After 
incubation with 5% NHS for 1 hour, T. b. brucei, T. lewisi and T. musculi (Partinico II 
strain) lysates were resolved by SDS-PAGE. Western blot analysis revealed a similar 
amount of ApoL-1 protein at 44 kDa, during endocytosis in all tested trypanosomes 
(Fig. 5). Using known quantities of NHS, these experiments indicated that 5×106 
trypanosomes would take up ApoL-1 at an equivalent of 0.31 µl of NHS. Interestingly, 
an unexpected band was observed in the trypanosome samples, which was about 55 
kDa, much larger than ApoL-1. The origins or identity of this protein is unclear. 
 
4. Discussion 
Emerging infectious diseases have been a major problem in global public health 
in recent times. Many of them are caused by pathogens from wild animals, for 
example, HIV and Zika from wild primates (Bush and Tebit, 2015, Dick, et al., 1952), 
SARS from bats (Li, et al., 2005), and avian flu from birds (Tan et al 2015). For these 
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reasons, human infections caused by animal trypanosomes such T. evansi and T. lewisi 
have also attracted great attention by the World Health Organization (WHO, 2005). 
These infections not only cause severe clinical signs but these pathogens are also 
distributed globally. The normal human serum incubation test, using target 
trypanosomes is a classic method for identifying the potential for human infectivity 
(Laveran and Mensnil, 1912). According to the literature, ApoL-1 occurs at a 
concentration of about 1070 - 2140 μg/ml in human serum (Da Silva, et al., 2011, 
2012). One μg/ml (0.1% NHS) ApoL-1could easily kill T. brucei, while T. lewisi 
could resist even 100 μg/ml (10% NHS) (Lun et al., 2015). Although, to our 
knowledge, T. musculi has not previously been reported as human infective, the risk 
of potential human infection is worrying due to similarities to the zoonotic 
trypanosome T. lewisi. Our results demonstrate that T. musculi is partially resistant to 
NHS both in vitro (0.31% NHS, corresponding to 3.3 - 6.6 μg/ml ApoL-1) and in vivo, 
which falls in to the category defined as sub-resistant (Hawking, 1976), unlike 
resistant T. lewisi or sensitive T. b. brucei.  Therefore, those T. lewisi-like human 
infection cases that have been reported should not be attributed to T. musculi.  
 A degree of resistance has also been reported in other animal trypanosomes, 
such as T. evansi (Da Silva, et al., 2011, 2012; Otto, et al., 2010) and T. congolense, 
whose resistance could be even further enhanced when continuously stimulated with 
non-lethal NHS (Lai, et al., 2010, Xong, et al., 2002). In addition, some other animal 
trypanosomes such as T. b. brucei and T. congolense can also infect humans for, as yet, 
unknown reasons (Truc, et al., 1998). Although the mechanisms of human infection 
by some animal trypanosomes, such as T. evansi, have been elucidated and shown to 
be due to a mutation of the ApoL-1 gene in patients (Joshi, et al., 2005, Vanhollebeke, 
et al., 2006), this is not always the case (Van Vinh Chau, et al., 2016).  
Although animal trypanosome infection of humans is not a major problem for 
public health at the present, there is a potential for risk in immunosuppressed 
members of the population. In fact, immunosuppressed patients infected with some 
insect trypanosomes, e.g. Leptomonas spp., have been reported (Ghosh, et al., 2012, 
Pacheco, et al., 1998, Srivastava, et al., 2010). This indicates that wild animal and 
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even insect trypanosomes can potentially naturally infect humans who are 
immunosuppressed or have other health problems. T. musculi may be unlikely to be 
able to infect humans in normal situations, but, due to the partial resistance to NHS, it 
could be a potentially high risk for people with immunodeficiency, such as patients 
with cancer, AIDS and organ transplantation. Since it is a globally distributed species 
in its mammalian hosts, there would be no spatial or environmental restrictions on its 
potential emergence.  
The mechanism of partial resistance of T. musculi against lysis by NHS is an 
interesting topic to consider. Based on our results from the endocytosis analysis, T. 
musculi and T. b. brucei as well as T. lewisi take up a similar amount of ApoL-1 
suggesting that the resistance of T. lewisi and T. musculi may not rely on a restriction 
in uptake of ApoL-1. Thus, it is probable that their resistance may depend on some 
mechanism which blocks the trypanolytic activity of ApoL-1. However, we were not 
able to subcellularly localize the ApoL-1 within T. musculi. Trypanosome membranes 
could bind a lot of host molecules by different mechanisms, without further 
endocytosis (Vincendeau and Daeron, 1989, Vincendeau, et al., 1986). This is an 
alternative explanation for the tolerance of T. musculi against ApoL-1. 
One well-characterized factor that is known to directly block the trypanolytic 
effect of ApoL-1 is the SRA protein. This is a truncated VSG-like protein and has 
been found to be expressed in T. b. rhodesiense (De Greef, et al., 1992, Xong, et al., 
1998). Attempts to identify SRA homologs in T. musculi and T. lewisi by PCR 
amplification were unsuccessful, indicating that a divergent protein(s) or mechanism 
is (are) operating in these rodent trypanosomes. Another molecular mechanism, which 
is active against NHS and found in T. b. gambiense, is linked to a VSG-like 
glycoprotein (TgsGP) and protects this trypanosome from ApoL-1 by stiffening 
endosomal membranes (Capewell, et al., 2013, Uzureau, et al., 2013). However, this 
mechanism is also unlikely to be operating in T. musculi and T. lewisi, as it was 
excluded by our endocytosis experiments. Although our findings suggest that T. 
musculi is unlikely to be a zoonotic pathogen, the identity of other T. lewisi-like 
human infective trypanosomes urgently needs to be investigated. In addition to the 
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morphological characteristics, molecular data (e.g. nuclear DNA or kinetoplast DNA 
barcodes) are necessary for species identification within the subgenus Herpetosoma 
(Hong, et al., 2017). Finally, genomic sequences of these two parasites may help to 
reveal their strategies that enable them to survive, or partially survive, in the presence 
of ApoL-1. 
Based on our results, we conclude that T. musculi was less sensitive to NHS than 
T. b. brucei, while it is more sensitive to NHS than T. lewisi. Therefore, those reported 
T. lewisi-like human infection cases should not be attributed to T. musculi. Although it 
is unlikely to be a zoonotic pathogen, we would advise caution in the case of 
immunocompromised people.  
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Figure legends. 
Fig. 1. The alignment of sequences of the 18S fragment (A) and haplotype 
networks (B) from T. lewisi, T. musculi and T. rangeli. 
 
A: PCR amplification of the 834-bp region of the 18S rDNA gene from T. lewisi and T. 
musculi for 35 cycles (98 oC for 10 s, 55 oC for 15 s, and 72 oC for 10 s). PCR 
products were grouped into 4 haplotypes, which were aligned using MEGA 5.2 
software with T. rangeli TryCC643 (EU867803) as an outgroup (TR). Polymorphic 
sites are indicated with an asterisk (*). TM includes three PCR sequences of T. 
musculi strains Partinico II, ATCC 30181 and ATCC 30182, and Genbank sequence of 
AJ223568. TL1 includes only T. lewisi WC365 (KP098535). TL2 includes four PCR 
sequences of T. lewisi CPO02, CPO04, CPO06, CPO07, and 7 Genbank sequences of 
T. lewisi TryCC34 (GU252210), TryCC35 (GU252211), TryCC43 (GU252212), 
TryCC44 (GU252213), TryCC1148 (GU252215), TryCC124 (GU252214) and Af 
(GU252209). TL3 includes 4 Genbank sequences of T. lewisi (HQ437158), Molteno 
B3 (AJ009156), TryRaIDN202 (AB242273) and LC244 (KP098536). TSP1 includes 
1 Genbank sequence of T. lewisi-like (DQ011519). TSP2 includes 1 Genbank 
sequence of T. lewisi-like in the patient’s house (DQ011520). 
B: Median-joining network inferred from T. lewisi, T. musculi and T. rangeli 
sequences. The haplotypes are indicated by the nodes. T. lewisi was split into 3 clades, 
T. musculi T. sp1, T. sp2 and T. rangeli assembled into 1 clade each, respectively. 
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Fig. 2. Trypanocidal effect of NHS on T. musculi Partinico II strain, T. b. brucei 
427 and T. lewisi in vitro. 
 
Trypanosomes (2x105/ml) were incubated with RPMI-1640 medium complemented 
with a serial dilution of NHS at 37°C with 5% CO2. The numbers of trypanosomes 
were counted using a haemocytometer by microscopy. Each measurement was 
performed in triplicate and repeated three times (n = 3). Statistical analysis between 
these are shown in Table S1. 
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Fig. 3. Parasitemia of T. musculi Partinico II strain in mice after pre-incubation 
with 10% NHS or FBS.  
 
Parasites were incubated in RPMI-1640 medium supplemented with 10% NHS or 
10% FBS (control) at 37°C for 24 hours and trypanosomes were then injected into 
mice intraperitoneally. Parasitemia was monitored daily and parasites were found in 
all mice on the eighth (FBS) and tenth (NHS) day post-infection (n = 5). Arrows 
indicate when we were unable to detect a parasitaemia. Significant differences 
(paired-sample t test) were indicated by asterisks (*, p<0.05; **, p<0.01; ***, 
p<0.001). 
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Fig. 4. Trypanocidal effect of NHS on the T. musculi Partinico II strain in vivo. 
Infected mice, with a parasitemia of 106 trypanosomes/ml, were intraperitoneally 
injected with 0.5 ml fresh NHS. Parasitemia was then monitored daily (n = 5). Mice 
inoculated with FBS were used as a control. Parasites in the mice were found two 
weeks after injection with fresh NHS or FBS, but the parasitemia in the mice 
inoculated with NHS was found to be lower than those in the control group. Arrows 
indicate when we were unable to detect a parasitaemia. Significant differences 
(paired-sample t test) were indicated by asterisks (*, p<0.05; ***, p<0.001). 
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Fig. 5. Western Blot detecting APOL-1 protein in T. musculi Partinico II strain 
after incubation with NHS.  
 
Parasites (5×106) were incubated in RPMI-1640 medium supplemented with 5% NHS 
or FBS at 37°C for 1 hour. All trypanosomes were harvested by centrifugation and 
washed twice with PBS and analyzed by SDS-PAGE. After blotting onto PVDF 
membrane, signals were detected using ApoL-1 polyclonal antibody (1:1000 dilution, 
Proteintech, China), HRP-conjugated 2nd antibody (Proteintech, China) and the 
reaction was detected using ECL (Thermofisher, USA).  
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Figure S1. In vitro trypanolytic effect of NHS on T. musculi strains of Partinico II 
(A), ATCC 30148 (B), ATCC 30181 (C) and ATCC 30182 (D) 
 
Trypanosomes were incubated with RPMI-1640 medium complemented with a serial 
dilution of NHS (5%, 2.5%, and 0%) at 37°C with 5% CO2. The numbers of 
trypanosomes were counted using a haemocytometer by microscopy. Each 
measurement was performed in triplicate and repeated three times (n = 3). Significant 
differences (independent-sample t test) of 5% NHS vs 0% NHS and 5% NHS vs 2.5% 
NHS were indicated by asterisks (*, p<0.05; **, p<0.01; ***, p<0.001). Significant 
differences (independent-sample t test) of 0% NHS vs 2.5% NHS were indicated by 
hash symbols (#, p<0.05; ##, p<0.01; ###, p<0.001). 
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Table 1. Origin of trypanosomes used in this work and their characteristics of 
lysis by normal human serum (NHS) in vitro over 24 hrs. 
 
Stocks Host Origin Isolate year Survival ratio 
in 2.5% NHS 
Phenotype 
T. b. brucei lister 427 
T. musculi Partinico II 
T. musculi ATCC 30148 
T. musculi ATCC 30181 
T. musculi ATCC 30182 
T. lewisi CPO02 
T. lewisi CPO04 
T. lewisi CPO06 
T. lewisi CPO07 
Bos taurus 
Unknown 
Unknown 
Mus domesticus 
Mus musculus 
Rattus rattus 
Rattus rattus 
Rattus rattus 
Rattus norvegicus 
Tanzania 
Partinico Italy 
Unknown 
Partinico Italy 
USA 
China 
China 
China 
China 
1956 
1969 
Unknown 
1962 
Unknown 
2008 
2008 
2008 
2008 
0.9 ± 0.2% 
23.2 ± 0.3% 
16.6 ± 4.9% 
16.2 ± 7.6% 
24.1 ± 0.4% 
80.5 ± 4.6% 
79.9 ± 6.8%* 
88.0 ± 11.6%* 
153 ± 16.8%* 
S 
R/R 
R/R 
R/R 
R/R 
R 
R 
R 
R 
S, sensitive to NHS; R/R, relatively resistant to NHS; R, resistant to NHS. Values of 
in vitro lysis are expressed as percentage survival and represent means of experiments 
and ± SD. Each measurement was performed in triplicate and repeated three times (n 
= 3). *, data were obtained from 10% NHS incubations (Lun et al., 2015). 
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Table S1. Statistics analysis of trypanolytic assays on T. brucei, T. lewisi and T. 
musculi with serial dilutions of NHS for a 3-24 hours incubation. P values between 
groups were shown. While 0.01<p≤0.05 were shadowed in black, 0.001<p≤0.01 were 
shadowed in white, p≤0.001 were black boxed in white. Groups with cells und 
countable that were unable to be subjected to the student t test are indicated with “-”. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T. brucei Incubation 0.31%NHS 0.63%NHS 1.25%NHS 2.5%NHS 5.0%NHS 10%NHS 
0%NHS 
6h p<0.001 p<0.001 p=0.005 p<0.001 p<0.001 p<0.001 
12h p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 
24h p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 
0.31%NHS 
6h 
 
p=0.1186 p<0.001 p<0.001 p=0.004 p=0.160 
12h 
 
p=0.3432 p<0.001 p<0.001 p=0.140 p=0.251 
24h 
 
p=0.2614 p<0.001 p=0.060 p=0.269 p=0.193 
0.63%NHS 
6h 
  
p=0.011 p=0.105 p=0.588 p=0.486 
12h 
  
p<0.001 p=0.002 p=0.527 p=0.043 
24h 
  
p<0.001 p=0.456 p=0.062 p=0.049 
1.25%NHS 
6h 
   
p=0.072 p<0.001 p<0.001 
12h 
   
p=0.118 p=0.002 p<0.001 
24h 
   
p<0.001 p<0.001 p<0.001 
2.5%NHS 
6h 
    
p=0.072 p=0.001 
12h 
    
p=0.007 p<0.001 
24h 
    
p=0.010 p=0.008 
5.0%NHS 
6h 
     
p=0.054 
12h 
     
p=0.016 
24h 
     
p=0.332 
T. lewisi Incubation 0.31%NHS 0.63%NHS 1.25%NHS 2.5%NHS 5.0%NHS 10%NHS 
0%NHS 
6h p=0.922 p=0.152 p=0.509 p=0.012 p<0.001 p<0.001 
12h p=0.817 p=0.595 p=0.814 p=0.233 p=0.012 p<0.001 
24h p=0.535 p=0.101 p=0.242 p=0.028 p=0.001 p<0.001 
0.31%NHS 
6h 
 
p=0.225 p=0.552 p=0.031 p<0.001 p=0.001 
12h 
 
p=0.743 p=0.984 p=0.310 p=0.016 p=0.251 
24h 
 
p=0.259 p=0.513 p=0.065 p=0.002 p=0.193 
0.63%NHS 
6h 
  
p=0.785 p=0.366 p=0.005 p=0.001 
12h 
  
p=0.774 p=0.521 p=0.046 p=0.002 
24h 
  
p=0.739 p=0.286 p=0.012 p<0.001 
1.25%NHS 
6h 
   
p=0.351 p=0.018 p=0.003 
12h 
   
p=0.354 p=0.026 p=0.001 
24h 
   
p=0.233 p=0.017 p<0.001 
2.5%NHS 
6h 
    
p=0.025 p=0.004 
12h 
    
p=0.142 p=0.007 
24h 
    
p=0.216 p=0.005 
5.0%NHS 
6h 
     
p=0.107 
12h 
     
p=0.128 
24h 
     
p=0.035 
T. musculi Incubation 0.31%NHS 0.63%NHS 1.25%NHS 2.5%NHS 5.0%NHS 10.0%NHS 
0%NHS 
3h 
6h 
9h 
p=0.727 
p<0.001 
  p=0.024 
p=0.010 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
12h p=0.005 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 
24h p=0.500 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 
0.31%NHS 
3h 
6h 
9h 
 
 
 
p=0.131 
p=0.024 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
12h 
 
p=0.002 p<0.001 p<0.001 p<0.001 p<0.001 
24h 
 
p=0.010 p<0.001 p<0.001 p<0.001 p<0.001 
0.63%NHS 
3h 
6h 
9h 
 
 
 
 
 
 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
p<0.001 
12h 
  
p<0.001 p<0.001 p<0.001 p<0.001 
24h 
  
p<0.001 p<0.001 p<0.001 p<0.001 
1.25%NHS 
3h 
6h 
9h 
 
 
 
 
 
 
 
 
 
p=0.001 
p=0.015 
p=0.003 
p<0.001 
p=0.015 
p=0.003 
p<0.001 
p=0.015 
p=0.003 
12h 
   
p=0.003 p=0.003 p=0.003 
24h 
   
p=0.006 p=0.006 p=0.006 
2.5%NHS  
and  
5.0%NHS 
3h 
6h 
9h 
 
 
 
 
 
 
 
 
 
 
 
 
- 
- 
- 
- 
- 
- 
12h 
    
- - 
24h 
    
- - 
